OTCMKTS:RHHBY Roche 7/23/2026 Earnings Report $50.50 -1.40 (-2.70%) As of 07/13/2026 03:59 PM Eastern ProfileForecast Roche EPS ResultsActual EPSN/AConsensus EPS $1.59Beat/MissN/AOne Year Ago EPSN/ARoche Revenue ResultsActual RevenueN/AExpected Revenue$38.34 billionBeat/MissN/AYoY Revenue GrowthN/ARoche Announcement DetailsQuarterDate7/23/2026TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesCompany Profile Roche Earnings HeadlinesIonis extends losses as Roche scraps two partnered studiesJuly 10, 2026 | seekingalpha.comTeva, Polpharma ink licensing pact for biosimilar targeting Roche’s OcrevusJuly 9, 2026 | seekingalpha.comThey proved it worked in '76. Then buried it.In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the project. Unocal and Texaco did the same. All three buried the results because it threatened their core business. Now one company has spent sixty years developing what Big Oil refused to touch. Google locked in a 15-year contract, Bill Gates wrote a $100 million check, and on August 18th the government hands it a competitive edge no other energy source receives.July 14 at 1:00 AM | Behind the Markets (Ad)Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAICJuly 7, 2026 | finance.yahoo.comGenentech and Roche Present New Data in Alzheimer's Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAICJuly 7, 2026 | businesswire.comRoche presents new data in Alzheimer's disease from across its integrated pharmaceutical and diagnostics portfolio at AAICJuly 7, 2026 | globenewswire.comSee More Roche Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Roche? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Roche and other key companies, straight to your email. Email Address About RocheRoche (OTCMKTS:RHHBY) is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY). In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies. The diagnostics business supplies a broad range of in vitro and molecular diagnostics, tissue‑based pathology solutions, point‑of‑care testing and diabetes care products, along with instruments and assay systems used by hospitals, laboratories and clinics to support clinical decision‑making and patient monitoring. Roche has a global footprint with operations and research facilities across Europe, the Americas and Asia, and a portfolio that combines internally developed products with offerings from affiliated biotech subsidiaries. The company emphasizes research and development and partnerships to advance precision medicine, leveraging its diagnostics expertise to support the selection and monitoring of appropriate therapies.View Roche ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Analysts See Major Upside for These 5 StocksMarketBeat Week in Review – 07/06 - 07/10Delta Air Lines Lives Up to Its Claims: Shares Can Keep ClimbingWhy WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software CostsPriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth Upcoming Earnings Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026)Bank of New York Mellon (7/15/2026)Morgan Stanley (7/15/2026)Progressive (7/15/2026)The PNC Financial Services Group (7/15/2026)Elevance Health (7/15/2026)Johnson & Johnson (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
